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Vaccine deliveryBecause of their large surface area and immunological competence, mucosal tissues are attractive administration
and target sites for vaccination. An important characteristic of mucosal vaccination is its ability to elicit local im-
mune responses, which act against infection at the site of pathogen entry. However, mucosal surfaces are
endowedwith potent and sophisticated tolerancemechanisms to prevent the immune system fromoverreacting
to the many environmental antigens. Hence, mucosal vaccination may suppress the immune system instead of
induce a protective immune response. Therefore, mucosal adjuvants and/or special antigen delivery systems as
well as appropriate dosage forms are required in order to develop potent mucosal vaccines.
Whereas oral, nasal and pulmonary vaccine delivery strategies have been described extensively, the sublingual
and buccal routes have received considerably less attention. In this review, the characteristics of and approaches
for sublingual and buccal vaccine delivery are described and comparedwith othermucosal vaccine delivery sites.
Wediscuss recent progress and highlight promising developments in the search for vaccine formulations, includ-
ing adjuvants and suitable dosage forms, which are likely critical for designing a successful sublingual or buccal
vaccine. Finally, we outline the challenges, hurdles to overcome and formulation issues relevant for sublingual or
buccal vaccine delivery.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Among public health interventions, vaccination is by far themost ef-
fective strategy in maintaining population health and combating infec-
tious diseases, especially in developing countries and disaster areas.
Vaccination saves millions of lives every year, while bringing numerous
social and economic benefits [1]. Since the vast majority of pathogens
infect their host through the mucosa, an ideal vaccine should induce
protective immunity at mucosal sites in order to act as a first line of de-
fense against infections. However, most of the vaccines currently in use
are administered via injection, e.g., via the subcutaneous or intramuscu-
lar route. This generally induces poor mucosal immunity, whereas vac-
cines administered via mucosal routes have proven to be effective for
the induction of both systemic and local immunity [2]. Additionally,mu-
cosal immunizationmakes vaccine delivery easier and safer than paren-
teral administration routes, is very suitable for mass immunization
during pandemic situations, and improves acceptability especially
among children [3,4].
Despite the advantages mentioned above, there are currently only
few mucosal vaccines for human use on the market [5]. The reason forklaan 9, P.O. Box 450, 3720 AL
),
. This is an open access article underthis is that mucosal vaccination poses several challenges, such as im-
mune regulation and tolerance, as well as overcoming fast removal of
the vaccine by body fluids and enzymes, as has been reviewed for the
oral [3,6], the nasal [7] and the pulmonary route [8]. Compared to the
above-mentioned traditional mucosal routes, sublingual and buccal
vaccine administration has received less attention. For many years,
these routes have been used for the delivery of low-molecular-weight
drugs to the bloodstream. Currently, the only vaccines that are widely
being used for delivery via the oral mucosae are therapeutic sublingual
allergy vaccines. These vaccines are used for sublingual immunotherapy
(SLIT) to treat allergic hypersensitivity. Sublingual delivery of allergens
can activate regulatory T cells that can suppress undesired immune
reactions [9]. This has resulted in several approved sublingual products
for allergy immunotherapy, such as SLITone®, Sublivac®, Grazax®,
Oralair®, and AllerSlit®forte. Allergy vaccines are reviewed by Valenta
et al. [10] and are beyond the scope of this review since they are
aimed at immune regulation (tolerance) instead of activation of the
adaptive immune system.
In this review, we will describe the potential and limitations of
the sublingual and buccalmucosae as vaccine delivery sites and themu-
cosal immune responses that are induced upon sublingual or buccal
vaccination. Further, the current status of sublingual and buccal vaccine
delivery will be discussed and suitable vaccine antigens and potent
adjuvants (immune potentiators and/or delivery systems) will be
highlighted. Appropriate dosage forms that are required for a successfulthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ing perspectives are given, including the existing research and develop-
ment gaps in this field and the potential of improved or controlled
release vaccine formulations for sublingual and buccal vaccine delivery.2. Sublingual and buccal mucosal sites for vaccine delivery
Mucosal vaccine delivery in the mouth can be subdivided into sub-
lingual and buccal delivery. Sublingual delivery occurs via the mucosa
of the ventral surface of the tongue and the floor of the mouth under
the tongue, whereas buccal delivery occurs via the buccal mucosa,
which is located in the cheeks, the gums and the upper and lower
inner lips (Fig. 1). The specific structure and cell composition of the sub-
lingual and buccal regions in the mouth define whether they are more
or less suitable for vaccine delivery (as described below).
Within the oral cavity, some mucosal regions are lined by a
keratinized stratified epithelium (gingival, hard palate, outer lips),
whereas other regions are lined by a non-keratinized stratified epitheli-
um (Fig. 1). The epithelium is supported by a basement membrane,
which separates the two major layers of the oral mucosa: the epitheli-
um and the underlying connective tissue or lamina propria. The ar-
rangement of the hard palate and gingival, including the pluristratified
keratinizedmucosal epithelium and the lamina propria that is anchored
onto the periostium of the underlying bone, makes these regions chem-
ically and mechanically resistant to withstand the shearing forces asso-
ciated with chewing food. The floor of the mouth, the inner surface of
the lips and cheeks, and the ventral side of the tongue are covered by
a non-keratinized epithelium, rendering these relatively more elastic
and pervious than keratinized mucosae, and thus potentially more suit-
able for drug or antigen delivery.
The epithelium serves as a mechanical barrier protecting the under-
lying tissues and consists of a basal layer, an intermediate layer, and a
superficial layer. From the basal to superficial layer the cells become
larger,more flattened,more proteinaceous in the formof proteinmono-
filaments, and less viable due to the absence of organelles (Fig. 2). The
compacted, flattened cells of the lower superficial and intermediate
layers form the major physical barrier to transport, whereas the inter-
cellular lipids play an important role in the permeability of the mucosa.
Besides the epithelial cells, the oral mucosal epithelium also contains
three other cell types. The basal layer includes Merkel cells, which are
endocrine cells associated with nerve fibers that contribute to the over-
all barrier function of the epithelium. They have also been suggested to
play a role in the regenerative processes of oral mucosa [11]. Further,Floor of the mouth
[SUBLINGUAL REGION]
Ventral side of the tongue
[SUBLINGUAL REGION]
Hard palate
Outer lip
Palatine tonsil
Fig. 1. The anatomy of the oral cavity. The sublingual anthe suprabasal layer contains two types of cells: melanocytes, which
produce the pigment melanin and are thus responsible for the color of
the mucosa; and Langerhans cells (LCs), which are the most superficial
antigen-presenting cells and an important target for the induction of an
immune response. Other antigen-presenting cells below themucosa are
themyeloid dendritic cells (mDCs) located along the laminapropria and
the plasmacytoid DCs (pDCs) found in the submucosal tissue (Fig. 2).
Salivary glands, which are located just below the mucosa in the
mouth, produce mucin, a major component of the mucus layer on the
mucosal surface, and help to promote the production and secretion of
saliva. Saliva is needed tomoisten and lubricate themucosae and assists
the masticatory process by binding the food bolus prior to and during
swallowing. Additionally, salivary secretions protect the oral epithelium
from potential harmful substances and regulate the composition of the
oral microbial flora by its enzyme activity and by maintaining the oral
pH between 5.5 and 7.0 [12].2.1. Implications for mucosal vaccine delivery and comparison with other
mucosal sites
Sublingual and buccal mucosae are attractive vaccine delivery sites
that may have advantages over other routes, because of their anatomy
andphysiology. Table 1 shows anoverviewof characteristics of different
sites that have been investigated for vaccine delivery. The dermal deliv-
ery site has been included because it contains comparable features with
the buccal and sublingual sites, such as the presence of LCs as a main
target for the vaccine antigen. However, dermal vaccination has the dis-
advantage that the impermeable thick keratinized stratum corneum
acts as a physiological barrier for the diffusion of antigens to reach LCs
after topical administration. As a result, dermal vaccination in general
needs chemical disruption and/or microneedle penetration of this wall
in order to let antigens reach the LCs to induce an immune response
[13]. In contrast, sublingual and buccal mucosae suitable for vaccine de-
livery lack keratinized epithelium.
Compared to gastro-intestinalmucosal routes, degradation by gastric
fluids and gastrointestinal enzymes is avoided during sublingual or buc-
cal delivery, although some enzymatic activity is present in the mouth.
Most of the mucosal routes have special ‘gateways’, the so-called
microfold (M) cells that are present in the epithelium covering the
follicles of mucosal tissues. These M cells take care of the transport of
antigens to mucosa-associated lymphoid tissues (MALT). The Peyer's
patches (PP), nasopharynx-associated lymphoid tissue (NALT) and
bronchus-associated lymphoid tissue (BALT) are important inductiveGingivae (gums)
[BUCCAL REGION]
Cheeks
[BUCCAL REGION]
Gingivae (gums)
[BUCCAL REGION]
Inner lip [BUCCAL REGION]
d buccal regions for vaccine delivery are indicated.
Langerhans cells (LC)
myeloid DCs (mDC)
plasmacytoid DCs (pDC)
mast cells (MC)
eosinophils (Eos)
CD4 T cells
CD8 T cells
MC
DRAINING
LYMPH NODE
T0
Eos SUBMUCOSA
Th
Treg
T0
CTL
MUCOSA
Lamina propria
antigen uptake by DCs
(30-60 min)
migration to draining
lymph nodes (12-24 h)
induction of adaptive
immune response (24 h)
migration to distant sites
basal layer
Fig. 2.Antigen delivery and antigen presentation following sublingual or buccal vaccination. Upon vaccine delivery, the antigen is likely to be captured by Langerhans cells (LC)within the
mucosa itself andmyeloid dendritic cells (mDCs) along the lamina propria. Antigen-bearing DCswill migrate to draining lymph nodes where they interact with naïve CD4 and CD8 T cells
to support the differentiation into effector T cells (i.e., helper (Th) and cytotoxic T cells (CTL)) and thereby induction of the adaptive immune response.
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gastro-intestinal (oral), nasal and pulmonary routes, respectively. In ad-
dition, the buccal and sublingual mucosal epithelia are covered withTable 1
Characteristics of different sites for vaccine delivery in humans. Mucosal immune responses (M
Sublingual Buccal Oral/ga
Estimated surface area
(cm2)
26.5 ± 4.2 50.2 ± 2.9 350,000
Epithelial structure
(cell layers)
Stratified squamous,
non-keratinized
Stratified squamous,
non-keratinized
Simple
non-cili
Thickness, cell layer 8–12 cells (0.1–0.2 mm) 40–50 cells (0.5–0.8 mm) Single c
Vaccine target LCs (oral lymphoid foci) LCs (oral lymphoid foci) M cells
MIR distinct sites:
Respiratory tract
Upper +++ ? −
Lower +++ ? −
Gastrointestinal tract
Stomach + ? +
Small intestine +++ ? +++
Colon ? ? ++
Reproductive tract +++ + −
Systemic response +++ ++ +
Abbreviations used:MIR: mucosal immune response; LCs: Langerhans cells; MALT:mucosa-ass
sue; BALT: bronchus-associated lymphoid tissue.
a Based on delivery in the small intestine.
b Strong response by aerosol administration.
c Total surface area lungs.
d Epithelium lining the trachea.
e Epithelium lining the bronchi.squamous stratified epithelium, whereas the epithelial cells of the
small intestine, nasal cavity, trachea and bronchi are covered with co-
lumnar epithelium.IR) after immunization by different routes are indicated [82].
stro-intestinal Intranasal Pulmonary Dermal
a 160–180 700,000 c 20,000
columnar,
ated a
Pseudo-stratified
columnar, ciliated
Pseudo-stratified d/
Simple columnar,
ciliated e
Stratified squamous,
keratinized
ell Single cell Single cell Multiple cells (2–3 mm)
(PP) M cells (NALT) M cells (BALT) LCs
+++ ? +++
+/+++ b ++ +++
− ? ?
− ? +
− ? +
++ ++ ?
+++ + +++
ociated lymphoid tissue; PP: Peyer's patches; NALT: nasopharynx-associated lymphoid tis-
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potential to induce mucosal immune responses in a broad range of tis-
sues (Table 1) as described in more detail in Section 2.2 (‘Mucosal im-
mune responses’).
Nagai et al. (2014) recently reported the transport of sublingual
antigens across sublingual ductal epithelial cells to ductal APCs in mice
[14]. Since different studies failed to detect specific sampling cells
(or M-like structures) in the sublingual or buccal mucosa [14,15],
it seems most likely that antigens cross the ductal epithelium via
paracellular and transcellular pathways [14]. So, probably the efficiency
of vaccine delivery via these routes is directly related to the permeabil-
ity of the mucosal membrane. This permeability is influenced by the
thickness and the degree of keratinization of these membranes. The
thickness of the human buccal mucosa has been estimated to be in the
range of 500–800 μm, whereas the mucosal thickness of the sublingual
region is about 100–200 μm [16]. In terms of permeability, the sublin-
gual region is more permeable than the buccal region, which in turn is
more permeable than the palatal region (Fig. 1). Sublingual administra-
tion can provide a rapid uptake of macromolecules and thus appears to
be an attractive route for dosage forms with a short delivery period.
In the development of sublingual or buccal vaccines, the presence of
saliva should be taken into account. Although saliva may be useful for
the release of the antigen from certain dosage forms, it can be disadvan-
tageous since the salivary composition, pH, and flow rate are variable.
Excessive secretion and salivary flow may dilute the antigen or lead to
swallowing of the dosage form before the antigen is absorbed through
the mucosa, the so-called ‘saliva washout’ [12]. Moreover, the presence
of digestive enzymes could lead to degradation of the antigen.
Since pH is a critical parameter for antigen absorption, the pH values
at the different oral mucosal sites should be kept in mind for successful
vaccine delivery. For example in adults, the pH of the floor of themouth
is about 6.5, whereas that of the buccal region is about 6.3 [17]. Howev-
er, factors, such as diet and saliva flow rate,may affect the pH of the oral
mucosa.
In Section 4 (‘Dosage forms’), we describe different ways to circum-
vent the challenging characteristics of sublingual or buccal vaccine
delivery.
2.2. Mucosal immune responses
Unlike small synthetic drugs, vaccine antigens do not reach the
bloodstream after entering the sublingual or buccal mucosa, but are
rather captured by antigen-presenting DCs, mainly LCs, in the mucosa.
The antigen uptake, process and the presentation of their epitopes to
T cells by antigen-presenting cells are required to induce effective
adaptive immunity. For example, the ovalbumin antigen crosses the ep-
ithelial barrierwithin 15 to 30min and the uptake by sublingual DCs oc-
curs within 30 to 60 min after sublingual administration in mice [18].
Rare pro-inflammatory cells, i.e., histamine-containing mast cells (MC)
or eosinophils (Eos) (Fig. 2), are found in oral tissues, and these cells
are mainly spread in the muscular layer beneath the mucosa [18,19].
Therefore, it is likely that most of the antigen is mainly captured by
LCs and other oral DCs in the upper layers prior to reaching pro-
inflammatory cells. The relatively high frequency of LCs and low num-
bers of mast cells in the buccal region [19] make the buccal mucosa an
attractive site for vaccine delivery despite its thicker epithelium and
lower permeability as compared to the sublingual mucosa.
Antigen-bearing DCs migrate to the lymph nodes draining the sub-
lingual and buccal area where they are able to prime both naïve CD4
and CD8 T cells (Fig. 2, T0 cells). For example, Eriksson et al. reported
that a substantial number of DCs leave the buccal epithelium after top-
ical buccal immunization and migrate to draining lymph nodes where
they present processed antigen to CD4 T lymphocytes [20]. Another
study revealed the buccal epithelium as inductive site of efficient prim-
ing of CD8 T lymphocytes [21]. Upon activation, T and B cells that leave
the site of the initial antigen presentation, enter the circulation and thendisperse to selected mucosal sites, where they differentiate into memo-
ry or effector cells. The activation of CD4 T lymphocytes leads to the
induction of antigen-specific helper T (Th cells) and/or regulatory
T cell (Treg) mediated immune responses (Fig. 2), whereas CD8 T cells
facilitate the induction of cytotoxic T lymphocyte (CTL) responses
(Fig. 2). The tissue destination of these cells appears to be largely deter-
mined by site-specific integrins, supposed ‘homing receptors’, on their
surface that will bind to mucosal tissue-specific receptors (addressins)
on vascular endothelial cells [22]. Recent work of Hervouet et al. dem-
onstrates that antigen-bearing DCs that have captured the antigen in
the sublingual mucosa are encountered in distant lymph nodes and
spleen following sublingual immunization of mice [23], which suggests
that sublingual DCs are capable to enter the blood circulation to seed
distant lymphoid organs.
The migration of immune cells from the inductive MALT to distant
effector tissues is the cellular basis for the so-called ‘common muco-
sal immune system’. The MALT contains T-cell zones, B-cell enriched
areas containing a high frequency of sIgA-positive B cells and a
subepithelial area with antigen-presenting cells to induce specific im-
mune responses. As mentioned earlier, the oral mucosa lacks a certain
immunological structure as observed in Peyer's patches of the intestine
where the antigen is sampled by specializedM cells. However, different
studies describe the concept of oral lymphoid foci, the equivalent of the
germinal centers observed in other MALT, suggesting that the oral
mucosa serves as a site for immune induction. The role of oral DCs in de-
ciding whether to induce adaptive immunity or tolerance, and whether
there exist germinal centers in oral lymphoid foci are discussed exten-
sively by others [24,25]. The distribution of immune cells, particularly
the abundant presence of oral LCs, makes the oral mucosa an attractive
site for vaccine delivery. Both sublingual and buccal immunization are
able to promote mucosal immunity, as well as systemic immunity,
against pathogens entering the human body at more distant sites than
the mouth (mucosa), such as the respiratory tract or reproductive
tract (Table 1).
3. Current status of sublingual and buccal vaccine delivery
In the section below, we will describe the use of live (attenuated)
pathogens, recombinant (heterologous expression) and inactivated
vaccines. Furthermore, wewill outline adjuvants, i.e., immune potentia-
tors and/or delivery systems, that have been evaluated for vaccination
via the sublingual or buccal route. A summary of the published studies
on sublingual and buccal vaccination is given in Table 2.
3.1. Live attenuated vaccines
3.1.1. Live attenuated viral vaccines
Sublingual immunization of mice with live attenuated influenza
virus (A/PR/8 strain, H1N1) has been found to be safe and effective for
inducing protective immune responses in mucosal and systemic com-
partments. Song et al. concluded that the observed protection was
mediated by the induction of influenza virus-specific IgG in the serum
and secretory IgA (sIgA) in the respiratory mucosa, which limit virus
entry and replication in the respiratory tract. A single sublingual dose
of A/PR/8 virus prevented lung pathology induced by influenza virus
challenge and provided a broad-range cross-protection against different
influenza virus subtypes. Thereby, the risk of potential passage of vac-
cine virus to the olfactory bulb was avoided by using the sublingual
route since no viral RNAwas detected in brains of sublingually vaccinat-
ed mice, in contrast to mice that received the same vaccine intranasally
[26]. Similarly, sublingual administration of live-attenuated virus lack-
ing the non-structural protein 1 (DeltaNS1) was as protective against
influenza virus challenges in mice as intranasal immunization. Sublin-
gual immunization with these DeltaNS1 viruses induced high levels of
virus-specific antibodies and stimulated immune cells in mucosa-
associated and systemic lymphoid organs [27]. Moreover, the vaccine
584 H. Kraan et al. / Journal of Controlled Release 190 (2014) 580–592was well tolerated and did not induce bodyweight loss in sublingually
vaccinated mice.
3.1.2. Recombinant virus based (RNA-) vaccines
Replication-defective adenovirus vectors (rAdV) have been widely
explored for the delivery of antigens. Infection by adenoviruses occurs
through the airway epithelium and replication takes place in mucosal
tissues of the respiratory tract. These characteristics make these
vectors suitable for mucosal vaccine delivery. Sublingual immunization
with rAdV encoding the conserved influenza nucleoprotein antigen [28]
or the soluble globular head of hemagglutinin [29] protected mice
against influenza virus infection. Furthermore, sublingual administra-
tion of rAd5 vectors encoding HIV proteins induced both significant
antigen-specific humoral (serum and mucosal IgG and IgA) [30] and
cellular (systemic and mucosal CTL responses) [31] immune responses.
Moreover, sublingual vaccination with rAdV encoding a truncated
S protein (rAdV-S), which is amajor antigenic protein present on severe
acute respiratory syndrome-associated coronavirus (SARS-CoV),
induced systemic neutralizing antibodies and airway IgA antibody re-
sponses in mice. These immune responses were similar to those in-
duced by intranasal administration. It is worth noting that intranasal
delivery of rAdV redirected the virus vector to the olfactory bulb, where-
as no adenoviral DNA was detected after sublingual delivery [32]. Choi
et al. reported that both mice and guinea pigs were protected against
a lethal Ebola challenge after a single sublingual immunization with
an AdV-based vaccine expressing the Zaire glycoprotein in a manner
similar to that of traditional intramuscular vaccination [33].
3.1.3. Recombinant bacterial vaccines
With the availability of genetic tools for heterologous gene expres-
sion, the concept of live vaccine vehicles has sparked renewed interest,
especially for the mucosal routes [34]. Several studies have shown
that engineered Bacillus (B) subtilis is able to generate systemic andmu-
cosal antibodies against heterologous antigens. B. subtilis delivered
sublingually and expressing tetanus toxin C-fragment, evoked protec-
tive immunity in both mice [35] and piglets [36]. Batista et al. reported
the use of ‘gut-colonizing’ B. subtilis spores as a newmucosal vaccine de-
livery platform consisting of two antigen expression strategies. One is
active during spore formation, which leads to the display of recombi-
nant adhesins at the spore surface that facilitates adhesion to mucosal
surfaces. In addition, the recombinant spores have been shown to ger-
minate after oral delivery resulting in intracellular expression of the an-
tigen. Mice immunized with three doses of B. subtilis spores via the
sublingual route, developed higher specific serum IgG titers when com-
pared with the mice orally immunized with a ninefold higher dose of
spores of the same strains. Although not proven in this study, the
authors speculated that sublingual delivery of these spores will also re-
sult in intracellular antigen expression once they are captured by
intraepithelial antigen-presenting cells and germinate [37]. The better
immune response to sublingual vaccination might be ascribed to the
fact that sublingual delivery has a smaller distribution volume and a
less aggressive environment than gastro-intestinal delivery.
3.2. Inactivated vaccines
In a study by Cho et al., different routes, i.e., intranasal, intravaginal,
transdermal, sublingual and intramuscular, were compared in a mouse
study using human papillomavirus 16L1 (HPV16L1) protein vaccine.
Among these routes, the intranasal and sublingual routes provided the
highest HPV16L1-specific levels of vaginal sIgA and systemic IgG re-
sponses that were comparable to those elicited via the intramuscular
route [45]. Sublingual vaccination against respiratory syncytial virus
(RSV) with a purified G protein fragment (Gcf) without the addition
of adjuvants induced strong serum IgG and mucosal IgA responses
(similar to intranasal vaccination) in mice. Interestingly, these antibody
responses could be elicited by Gcfwithout the need for an adjuvant. Thestudy demonstrated that the chemotactic activity exhibited by Gcf was
necessary to induce protective immunity. Therefore, the authors pro-
posed that Gcf has a self-adjuvanting property [46].
Murugappan et al. investigated whether sublingual administration
of whole β-propiolactone (BPL)-inactivated influenza virus can prime
the immune system for a later intramuscular boost with a heterologous
vaccine. Although sublingual priming did not induce any detectable
immune responses, it strongly enhanced hemagglutination inhibition
(HI) titers against both the homologous aswell as the heterologous vac-
cine after the intramuscular booster. In addition, sublingual priming
induced IgA responses in the lung and nose, while intramuscular prim-
ing showed higher IgA responses in the lung, but not in the nose [40]. In
a study by Song et al., a sublingual boosterwas given, instead of an intra-
muscular booster, and immune responses were analyzed more exten-
sively. Immunization with formalin-inactivated influenza virus via the
sublingualmucosa induced protective immune responses, elevatedmu-
cosal sIgA antibody levels, and enhanced virus-specific CTL responses
[26]. The different procedures used for virus inactivation affect the
membrane fusion properties of the virus to a certain extent, resulting
in a less optimal activation of CTLs. Inactivation with formalin severely
compromises fusion activity of the virus, while BPL-inactivation reveals
preservation of the fusion activity [60]. However, a sublingual booster
vaccinationwith formalin-inactivated influenza induced significant ele-
vated virus-specific CTL responses in mice. Unfortunately, the analysis
of CTL activation is lacking in the study using BPL-inactivated influenza.
As with mucosal immunization in general, sublingual (and buccal)
vaccination with non-replicative antigens does not induce sIgA and
serum IgG responses without the addition of adjuvants. Strong immune
potentiators or delivery systems are needed to break mucosal tolerance
and facilitate uptake through the oral mucosae. For example, a mucosal
adjuvant (cholera toxin, CT) was needed to induce immune responses
upon sublingual immunization with a human immunodeficiency virus
(HIV) subunit vaccine [48]. Çuburu et al. evaluated the sublingual route
for vaccine delivery using ovalbumin (OVA) as a model antigen.
The mice received three doses of 200 μg OVA and although systemic
IgG responses were measurable, mucosal OVA-specific antibody re-
sponses were absent after sublingual immunization of OVA alone. Co-
administration of a mucosal adjuvant (CT) generated high OVA-specific
IgA responses in saliva and nasal wash. These responses were of the
same magnitude as those induced by intranasal administration [58].
Recently, sublingual administration of a subunit influenza vaccinewas
evaluated in mice. After three doses, detectable, but rather low, antigen-
specific systemic IgG andHI titerswere found after sublingual immuniza-
tion, whereasmucosal IgA antibodieswere below the detection limit. The
addition of the mucosal adjuvant LTK63 was needed to those obtained
after conventional intramuscular immunization [41]. A Salmonella vac-
cine consisting of sonicated Salmonella proteins induced protection only
after sublingual immunization in the presence of adjuvants (CpG DNA
or CT). This was observed in both adult [51] and neonatal mice [50].
Although mucosal adjuvants improve immune responses upon sub-
lingual immunization using non-replicating/inactivated antigens, in
some studies systemic and/or mucosal immunity was obtained with
sublingual delivery of non-adjuvanted inactivated (subunit) vaccines
[45,46,58]. In general, high doses were used and even the size of the an-
tigen seemed to be an issue for successful immunization since small
proteins/antigens showed the induction of both systemic and mucosal
immune responses upon sublingual administration.
3.3. Adjuvants used in buccal and sublingual vaccines
3.3.1. Immune potentiators
3.3.1.1. Bacterial enterotoxins. The most powerful and hence the best-
studied mucosal adjuvants are the bacterial enterotoxins cholera toxin
(CT) and the Escherichia coli heat-labile toxin (LT), which have structur-
al and biological similarities.
Table 2
Preclinical development of sublingual and buccal vaccines.
Antigen Adjuvant In vivo
model
Dose (no. of doses) Dosage form
(volume)
Protection Immune response/characteristics Ref
Live attenuated vaccines
Influenza A/PR/8 Mouse 1 × 102 pfu
1 × 104 pfu
L
b7 ul
+/− - Both systemic and mucosal Abs
- Dose dependent protection against both homologous and heterosubtypic influenza virus challenge
[26]
deltaNS1 influenza A1 Mouse 2 × 107 pfu L
4 × 5 ul
+ - Protection against challenge with homologous and heterosubtypic influenza virus
- High levels specific Abs in both mucosal and systemic compartments
- Stimulated immune cells in mucosa-associated and systemic lymphoid organs
[27]
Heterologous antigen expression — live vaccine carriers
NP (nucleoprotein)
of influenza A/PR/8
rAd5 Mouse 1 × 107 pfu
1 × 108 pfu
L
b5 μl
− - Single sublingual immunization failed to confer protection by different influenza strains [28]
HA soluble globular head rAd5 Mouse 1 × 108 pfu L
10 μl
+ - Complete protection after challenge with lethal dose homologous virus
- Induction of significant levels of HA-specific mucosal IgA and IgG
[29]
RSV - sFsyn2 HDAd2 Mouse 1 × 108 pfu L
5 μl
+ - RSV F protein-specific systemic and mucosal neutralizing Abs
- RSV-specific IFN-γ producing CD8+ T cell responses in the spleen and lung
- Effective protection against RSV infection; reduced lung viral titers upon challenge compared with
control group
[38]
SARS-S protein (Spike) rAd Mouse 2 × 107 pfu
1 × 108 pfu
L
20 μl
n.d. - SARS-CoV neutralizing antibodies in serum
- Airway IgA
- Induced CD8+ T cells responses in lungs
- Unlike intranasal vaccination, no redirection of AdV to olfactory bulb
[32]
HIV-Env (Envelope glycoprotein) rAd5 Mouse 1 × 108 pfu L
10 μl
n.d. - Serum IgA response
- Vaginal IgA and IgG
[31]
HIV-Gag rAd5
rEA
Mouse 1 × 1010 pfu L
8 μl
n.d. - Induction of CTL responses in spleen and SMLN
- Higher innate immune responses and improved T cell responses after co-administration with rEA
(TLR agonist)
[30]
SIV-Env/rev SIV-Gag rAd5 Macaque 1 × 109 pfu Each (2×) L
0.25 ml
n.d. - Macrophage targeting in BAL fluid and rectal tissue
- SIV-specific cellular responses, serum binding Abs and mucosal sIgA
[39]
Ebola ZGP (Zaire glycoprotein) rAd5 Mouse
Guinea pig
1 × 108 pfu
1 × 109 pfu
L
10 μl
40 μl
+ - Induced IFN-y T cells in spleen, BAL, MLN and SMLN
- Elicited population of effector memory CD8+ cells and strong CTL responses in spleen and SMLN
[33]
Tetanus toxin fragment C (TTFC) Bacillus subtilis mLT Mouse 1 × 109 pfu (3–4×) L
10 μl
+ - Tetanus-specific systemic IgG and mucosal sIgA
- Full protection against lethal toxin challenge in mice immunized with TTFC vegetative cells
(without mLT)
[35]
Tetanus toxin fragment C (TTFC) Bacillus subtilis mLT Pig 1 × 109 pfu (4×) L
1 ml
n.d. - Tetanus-specific systemic neutralizing Abs
- Induction of salivary and vaginal IgA responses
[36]
Streptococcus mutans P1 Bacillus subtilis Mouse 1 × 108 pfu L
10 μl
n.d. - Higher specific IgG titers when compared to group orally immunized with higher dose [37]
Inactivated vaccines
Influenza WIV
(β-propiolactone-inactivated)
Mouse 20 μg (1×)
5 μg (i.m. booster)
L
10 μl
n.d. - Enhanced HI titers after sublingual priming followed by an intramuscular booster when compared
to the intramuscular priming
- Enhanced lung and nose IgA titers with sublingual priming
[40]
Influenza WIV
(formalin-inactivated)
Mouse 20 μg (2×) L
b7 μl
+ - Specific systemic and secretory Ab responses
- 80% survival
[26]
Influenza WIV
(formalin-inactivated)
mCTA-LT3 (5 μg) Mouse 20 μg (2×) L
b7 μl
+ - 100% survival, complete clearance of virus in the lungs (BAL fluid)
- More IFNy-producing CD4+ and CD8+ T cells in spleens and MLNs than without mCTA-LT
- More virus-specific CTL-responses than with PBS or killed A/PR/8 alone
[26]
Influenza HA subunit LTK634 (5 μg) Mouse 10 μg (3×) L n.d. - Systemic responses (IgG and HI) comparable to intramuscular immunization
- Influenza-specific Th17 cells and neutralizing mucosal IgA in the nose
(comparable to intranasal immunization)
[41]
Influenza A virosome c-di-GMP5 (7.5 μg) Mouse 2 μg (2×) L
7 μl
n.d. - Induction of systemic and local Abs capable of hemagglutination inhibition
- Significant adjuvant effect on both systemic and local Ab responses
- High frequencies of influenza-specific homo- and hetero-subtypic CD4+ Th1 cells
- Balanced Th1/2 profile and Th17 response after immunization with adjuvanted virosomes
[42]
Influenza 3M2eC protein CT (2 μg) Mouse 10 μg + [43]
(continued on next page)
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Table 2 (continued)
Antigen Adjuvant In vivo
model
Dose (no. of doses) Dosage form
(volume)
Protection Immune response/characteristics Ref
L
15 μl
- Both systemic and mucosal Abs
- Protection against both homologous and heterosubtypic influenza virus challenge
HPV16L1 VLP Mouse 5 μg L
10 μl
+ - Protection against genital challenge with HPV pseudovirions
- Neutralizing Abs in serum and genital IgG and IgA Abs
- Neutralizing Abs in cervicovaginal secretions
[44]
HPV16L1 VLP CT (2 μg) Mouse 5 μg L
10 μl
+ - Protection against genital challenge with HPV pseudovirions
- Higher systemic IgG Ab titers than after sublingual VLP administration without CT
- Lower vaginal IgG, but higher vaginal IgA Ab responses than intramuscular immunized mice
with alum-adjuvanted VLPs
- Neutralizing Abs in cervicovaginal secretions
[44]
HPV16L1 VLP Mouse 30 μg
50 μg
L
10 μl
n.d. - Higher vaginal and salivary sIgA responses when compared to untreated animals
- Increased number IFN-γ producing CD8+ T cells in spleen
[45]
HPV16L1 VLP CTB (10 μg) Mouse 30 μg L
10 μl
n.d. - Elevated mucosal sIgA induction after co-treatment with CTB
- Enhanced production of IL-4 and IFN-y from stimulated CD4+ T cells
- Higher number IFN-γ producing CD8+ T cells in spleen and SMLN when compared to HPV16L1
alone
[45]
HPV16L1 VLP Several adjuvants
(see characteristics)
Mouse 30 μg L
10 μl
n.d. - No enhanced effects on systemic IgG nor on vaginal and salivary IgA Ab responses
(Adjuvants that were used are: Poly I:C (0.1 mg), MPLA (10 μg), Imiquimod (50 μg), L18-MDP
(1 μg), Murabutide (10 μg), peptidoglycans (50 μg), Vitamin D3 (0.5 μg), γ-polyglutamic
acid (1 mg))
[45]
RSV G protein (Gcf) CT (2 μg) Mouse 20 μg L
15 μl
+ - Strong serum IgG and mucosal IgA responses
- Protection against RSV challenge without significant lung eosinophilia
- No adjuvant effect of CT
[46]
Measles virus NP Mouse 30 μg (1×) L
15 μl
+/− - Single buccal immunization (injection or topical application) induced antigen-specific CD8 CTLs
- Rapid recruitment of DCs into the mucosa
- Protection against lethal challenge following buccal vaccination by injection (100%) or topical
administration (40%)
[47]
HIV-1 Pol CTB
CT (1 μg)
Mouse 25 μg (3×) L
5 μl
n.d. - CTB-Pol conjugate induced IFN-γ producing CD8 T cells
- Induction of mucosal CTLs in the genital tract after immunization with CTB-Pol mixed with CT,
but not with CTB-Pol alone or Pol mixed with CT
[48]
HIV-1 gp41 CT (1 μg) Mouse 10 μg (3×) L
5 μl
n.d. - Strong specific IgG and IgA responses in serum and genital secretions after gp41 + CT
immunization
- gp41-specific IgA and IgG ASCs in genital tract
[48]
HIV-1 CN54gp140 (gp140) FSL-1
Poly I:C
MPLA
Pam3CSK4
R848
CpG B (20 μg each)
Mouse 10 μg (3×) L
10 μl
n.d. - Increased serum IgG and IgA titers when co-administered with Poly I:C
- Diminished systemic specific Ab responses with MPLA
- Detected IgA titers in vaginal washes of all animals where antigen was administered with
FSL-1, poly I:C, Pam3CSK4 or CpG B
[49]
HIV-1 CN54gp140 (gp140) Chitosan (100 μg) Mouse 10 μg (3×) L
10 μl
n.d. - No significant adjuvant effect of chitosan [49]
Salmonella proteins (SPP) Mouse
(newborn)
6/40 μg
(3 + 1)
L
1.2 μl
− - Slightly enhanced systemic IgG titer and mucosal IgA responses compared to the PBS control group [50]
Salmonella proteins (SPP) CT
(0.2/1 μg)
CpG
(1/10 μg)
Mouse
(newborn)
6/40 μg
(3 + 1)
L
1.2 μl
+ - Enhanced antigen-specific systemic IgG and mucosal sIgA responses in CT or CpG groups
compared to mice immunized with SSP alone
- Protection against intestinal necrosis and higher survival rates for adjuvant groups
[50]
Salmonella proteins (SPP) CT (1 μg)
CpG (10 μg)
Mouse 40 μg
(7×)
L
10 μl
+ - Significant higher antigen-specific sIgA responses for both groups immunized with SPP alone or
together with CT or CpG as adjuvant
- Higher IFN-γ production in spleen upon SPP-CpG vaccination
- Higher IL-4, IL-5 and IL-6 production in spleen upon SPP-CT vaccination
- Protection against intestinal necrosis and higher survival rates for adjuvant groups
[51]
Pneumococcal whole cell
(chloroform inactivated)
dmLT Mouse 10 μg (3×) L
5 μl
+ - Dose-dependent protection in sublingual immunized mice (reduced bacterial load in nasal wash
compared to control mice)
- Induced systemic IL-17A levels upon sublingual vaccination
[52]
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Helicobacter pylori lysate CT (10 μg) Mouse 500 μg
(2×)
L
10 μl
+ - Enhanced proliferative responses to H. pylori antigens in CMLNs
- Immune protection against H. pylori infection
- Strong specific serum IgG and IgA titers in stomach and intestine
- Strong proliferation and IFN-γ and IL-17 production by T cells from spleen and MLNs
- Increased IFN-γ and IL-17 gene expression in stomach
[53]
Helicobacter pylori lysate CT (10 μg) Mouse 500 μg L
10 μl
n.d. - Increased expression of chemokines and chemokine receptors known to attract eosinophils,
T cells and neutrophils
- Higher counts of CD4+ T cells, eosinophils, neutrophils and CD103+ DCs in the gastric lamina
propria of immunized mice
[54]
Helicobacter pylori lysate CT (10 μg) Mouse 400 μg L
10 μl
- Decrease in bacterial load after challenge when compared to non-immunized control group [55]
Helicobacter pylori lysate dmLT (10–20 μg) Mouse 400 μg L
10 μl
+/− - Decrease in bacterial load after challenge when compared to non-immunized control group
- Enhanced ex vivo proliferative and cytokine responses from cells from spleen and MLNs after
restimulation with H. pylori antigens
[55]
Chlamydial major outer
membrane protein (MOMP)
CTA1-DD (20 μg) Mouse 100 μg L
7 μl
+/− - Reduction of severity and incidence of genital tract pathology after challenge with Chlamydia
muridarum after sublingual vaccination with or without adjuvant
- 80% of the MOMP-CTA-DD-immunized animals protected in genital tract
[56]
Chlamydial major outer
membrane protein (MOMP)
CT-CpG (5 μg CT)
(10 μg CpG)
Mouse 100 μg L
7 μl
+/− - Reduction of severity and incidence of genital tract pathology after challenge with Chlamydia
muridarum after sublingual vaccination with or without adjuvant
- 60% of the MOMP-CT-CpG-immunized animals protected in genital tract
- Reduction of duration of vaginal shedding after challenge, but not of the total bacterial burden
- MOMP-specific IFN-γ, TNF-α and IL-17 cytokine production by lymphocytes isolated from MLNs
[56]
Tetanus toxoid (TT) LT (1 μg) Mouse 10−20 μg
(4×)
L
5 μl
n.d. - Induced systemic TT-specific IgG and mucosal IgA levels after TT-LT immunization when
compared to TT alone
- Long lasting TT-specific ASCs in bone marrow and CD4+ and CD8+ T cells in dLNs and spleen
[57]
Tetanus toxoid (TT) LTK63 (10 μg) Mouse 10–20 μg
(4×)
L
5 μl
n.d. - Induced systemic TT-specific IgG and mucosal IgA levels after TT-LTK63 immunization when
compared to TT alone
- Long lasting TT-specific ASCs in bone marrow and CD4+ and CD8+ T cells in dLNs and spleen
[57]
Tetanus toxoid (TT) FSL-1
Poly I:C
MPLA
Pam3CSK4
R848
CpG B (20 μg each)
Mouse 10 μg
(3×)
L
10 μl
n.d. - Significant increase in specific systemic IgG when co-administered with FSL-1, poly I:C, CpG B
and an increase in IgA for FSL-1
- Detectable IgG titers in vaginal washes of all animals where antigen was administered with
FSL-1, poly I:C or CpG B
- Decreased specific systemic and vaginal IgA responses for TT-MPLA-immunized mice
[49]
Tetanus toxoid (TT) Chitosan (100 μg) Mouse 10 μg (3×) L
10 μl
n.d. - Increase in specific systemic IgG and IgA above TT alone when co-administered with chitosan
- Increased IgG1/IgG2a ratio relative to TT alone
[49]
Ovalbumin (OVA) CT (2 μg) Mouse 200 μg (3×) L
b10 μl
n.d. - Systemic and mucosal Ab responses
- Balanced Th1/Th2 cytokine responses
- Induction of CD8+ T cells in lung tissues and systemic lymphoid organs
[58]
Ovalbumin (OVA) Ad2F (25 μg) CT (2 μg) Mouse 25 μg (3×) L
7 μl
n.d. - Ad2F-delivered OVA was efficiently taken up by DCs and migrated mostly to SMLNs
- Highest OVA-specific serum IgG, IgA and mucosal IgA titers for OVA-Ad2F + CT-immunized mice
- Mixed Th-cell response by enhanced IL-4, IL-10, IFN-γ and TNF-α-specific cytokine-forming cells
[59]
Ovalbumin (OVA) CT (2 μg) Mouse 200 μg (3×) L
5 μl
n.d. - OVA-specific IgG and IgA Abs in blood and cervicovaginal secretions
- IgA ASC in genital mucosa upon sublingual immunization similar to intranasal or vaginal
immunization and superior to intragastric vaccination
- OVA-specific effector CD8-positive CTLs in genital mucosa following sublingual immunization
with OVA and CT
[44]
Hcβtre (from Botulinum
neurotoxin A)
Ad2F (25 μg) CT (2 μg) Mouse 25 μg (5×) L
7 μl
+ - 100% protection against BoNT/A intoxication for Hcβtre-Ad2F + CT-immunized mice
- ~60% protection against BoNT/A intoxication for Hcβtre + CT-immunized mice
[59]
Abbreviations: Abs: antibodies; ASC: antibody secreting cells; CTL: cytotoxic T cell;HA: hemagglutinin;HIV: human immunodeficiency virus; (m)CT: (mutant) cholera toxin; CTA/B, A/B subunit of CT; (m)LT: (mutant) heat labile toxin; LTB, B subunit of LT; dmLT,
double mutant LT;MPLA:monophosphoryl lipid A; rAd: recombinant adenoviral vector; rEA: recombinant Eimeria tenella; RSV: respiratory syncytial virus; SARS: severe acute respiratory syndrome-associated coronavirus; SIV: simian immunodeficiency virus;
WIV: whole inactivated virus.
1 Influenza virus lacking the Nonstructural Protein 1.
2 Vaccine based on helper-dependent adenoviral vector expressing the soluble fusion glycoprotein of RSV.
3 Subunit mutant of cholera toxin (CT) E112K with the pentameric B subunit of LT.
4 Mucosal adjuvant, K63 mutant of LT.
5 Mucosal adjuvant, (3′,5′)-cyclic dimeric guanylic acid.
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588 H. Kraan et al. / Journal of Controlled Release 190 (2014) 580–592The adjuvant effect of sublingually administered CT has been docu-
mented with a number of antigens, including influenza [43] and HIV
[48] subunit vaccines, Salmonella proteins [50,51] and Helicobacter
pylori lysates [54,55] with the latter two as undefined vaccines. LT,
when co-administered sublingually with tetanus toxoid (TT) induced
higher specific IgG and mucosal IgA antibody titers when compared to
TT alone [57]. However, CT and LT cause severe diarrhea in humans
and are involved in the clinical occurrences of cholera and enterotoxi-
genic E. coli enteritis, and therefore not suitable as an oral or sublingual
adjuvant for human use [61–63]. Since enterotoxicity is mainly caused
by the enzymatically active A-subunit, mutated enterotoxins with re-
duced toxicity but retained adjuvant properties, have been developed.
LT(R192G), also namedmLT, showed reduced toxicity inmice, butmain-
tained its adjuvanticity to a level nearly equivalent to that of LT [64,65].
Building on this mutant, a double mutant of LT, R192G/L211A or dmLT,
showed adjuvanticity for a co-administered antigen equivalent to mLT
upon oral administration (gastro-intestinal delivery) [66]. Recently,
dmLT has been evaluated as an adjuvant for sublingual and buccal vacci-
nation with a whole-cell pneumococcal vaccine that induces protection
inmice [52]. In the search for an alternative adjuvant for aH. pylori lysate
vaccine, dmLT was compared to CT. Earlier studies have shown that a
strong mucosal adjuvant like CT was needed to induce protective im-
mune responses against H. pylori infection. Sublingual immunization
with H. pylori lysate and dmLT significantly decreased the bacterial bur-
den after H. pylori infection compared to unimmunized mice and to the
same extent as when using CT as adjuvant [55]. Moreover, cellular im-
mune responses that are known to correlate with protection were also
fully comparable when using dmLT and CT as adjuvants.
In a study by Cho et al., HPV16L1 protein provided both vaginal and
salivary sIgA, and serum IgG responses after sublingual administration
in mice (150 μg) [45]. Several adjuvants were tested, including the
B subunit of cholera toxin (CTB), three toll-like receptor agonists (i.e.,
Poly(I:C), MPL, imiquimod), three nucleotide-binding oligomerization-
domain agonists (L18-MDP, murabutide, PGN), vitamin D3 and poly-
gamma-glutamic acid. Among the adjuvants tested, only CTB provided
improved mucosal sIgA and systemic IgG induction. Sublingually ap-
plied CTB also enhanced the production of IL-4 and IFN-y by stimulated
CD4+ T cells from the spleen, as well as the number of IFN-y producing
CD8+ T cells that were isolated from the spleen or submandibular
lymph node (SMLN). The other adjuvants had no effect on the immune
response when compared to the unadjuvanted control [45].
3.3.1.2. Toll-like receptor (TLR) ligands. Despite the negative results men-
tioned above, TLR agonists can significantly improve immune responses
after sublingual vaccination. Amouse study evaluating TLR agonists (i.e.,
FSL-1, Poly(I:C), monophosphoryl lipid A (MPLA), Pam3CSK4, R848, cy-
tosine–phosphate–guanosine (CpG)) in different mucosal routes using
HIV gp140 and a tetanus toxoid revealed clear differences in immuno-
genicity [49]. MPLA, a TLR-4 agonist, suppressed systemic responses
when administered sublingually, while the responses were enhanced
after intranasal or subcutaneous immunization. CpG, a TLR-9 ligand,
evoked enhanced immune responses upon sublingual and intranasal
immunization whereas it did not affect the responses after subcutane-
ous immunization [49]. Another study revealed that sublingual immu-
nization with an Ad5 vector expressing a TLR agonist derived from
Eimeriatenella significantly activated NK cells, natural killer T (NKT)
cells, B cells, and CD4+ T cells in the spleen. In addition, the number of
cells expressing MHC-II increased [30].
Bacterial DNA or synthetic oligodeoxynucleotides (ODNs) contain-
ing CpG motifs act as mucosal adjuvants. These TLR 9 ligands induced
strong Th1 responses in mice after sublingual delivery of a Salmonella
vaccine [67].
3.3.2. Delivery systems
Virus-like particles (VLPs) and virosomes have been evaluated
for sublingual delivery. Cho et al. showed that sublingual delivery ofHPV16L1 VLPs in mice induced systemic IgG and mucosal sIgA re-
sponses that were similar to the intranasal route, but significantly
higher compared to other delivery (intravaginal, transdermal, intra-
muscular) routes [45]. In contrast to this study in mice, a clinical trial
by Huo et al. with Gardasil® (Sanofi Pasteur), which contains the
same L1-based VLPs from HPV but is co-administered with aluminum
hydroxyphosphate as an adjuvant, showed that sublingual immuniza-
tion is much less effective than intramuscular immunization [68]. How-
ever, this alumadjuvanted VLP formulation is not suitable for sublingual
HPV vaccination,which is likely due to the fact that alum adjuvants con-
sist of relatively large (micrometer range) particles that are probably
poorly taken up by mucosal epithelial cells. Other adjuvants as well as
improved dosage forms (see Section 4) may help to increase the im-
mune response to the VLPs.
A sublingual vaccine containing influenzaH5N1virosomes (2 μgHA)
in combination with themucosal adjuvant (3′,5′)-cyclic diguanylic acid
(c-di-GMP) effectively induced local and systemic H5N1-specific hu-
moral and cellular immune responses in mice. The systemic IgG and
nasal sIgA antibody levels were lower than those induced by intranasal
administration, but the IgG levels were comparable to those obtained
after intramuscular administration, whereas nasal sIgA levels were
higher than the levels upon intramuscular administration [42].
4. Dosage forms
Optimized dosage forms may improve the performance of sublin-
gual and buccal vaccines substantially. Several dosage forms exist for
sublingual and buccal delivery of marketed drugs. These range from
droplets, sprays, and orally disintegrating tablets to oral films. However,
only a few dosage forms have been used to explore sublingual or buccal
delivery of vaccines. Almost all sublingual vaccination studies reported
here have been performedby the simple application of droplets of a vac-
cine under the tongue. There are no studies on the role of potentially
crucial variables, like contact time, vaccine viscosity and antigen release
kinetics on immunogenicity.
In pre-clinical studies, vaccine droplets are applied under the tongue
on the floor of the mouth and the animal is kept under sedation for less
than 1 h to allow the vaccine to be taken up (see Table 2). For sublingual
vaccination of mice 5 μl can be applied sublingually without transfer of
the vaccine to the stomach (including a sedation time of 30min) [48,57].
Sublingual administration of allergens to humans by droplets has
been used for years in Europe in sublingual immune therapy (SLIT)
against allergies. Typically, in SLIT, droplets of a highly viscous glycerol
formulation containing the allergen extract are applied under the
tongue. The high viscosity contributes to antigen retention under the
tongue and as such facilitates the efficacy of the immune therapy.
In a recent clinical trial, HPV vaccine was applied sublingually to
humans. Compared to SLIT with glycerol droplets, a relatively compli-
cated administration protocol was used in this study. In brief, subjects
rinsed their mouths with water, the sublingual area was dried and
then 0.5 ml of vaccinewas applied on the floor of themouth. Adsorbent
padswere applied in themouth to absorb the saliva during and after the
vaccine application. Despite the elaborate administration protocol, in
only three of the twelve subjects were virus-neutralizing antibodies in-
duced in serum after three standard doses of HPV vaccine via the sublin-
gual route. These neutralizing antibody titers were still 1000-fold lower
than in the intramuscular group. Researchers concluded that alternative
delivery systems and adjuvants would be required to enhance and eval-
uate immune responses following sublingual immunization in humans
[68].
The disappointing results of this clinical trial may be related to sev-
eral factors. First, a significant amount of solution (0.5 ml versus ‘a cou-
ple of droplets’ in SLIT therapy) was applied. Despite the extensive
administration protocol, a certain high volume will easily be digested
and will follow the gastro-intestinal route. Secondly, the vaccine used
in the study (Gardasil®) is a VLP based vaccine containing aluminum
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large particle size (in the range of 1 μm) and thus is not ideal for transfer
over membranes. Finally, alum is not known to be a good adjuvant for
mucosal vaccination.
Droplets for improved (extended) mucosal retention are currently
under development by PATH [69]. Their technology is based on a
thermo-responsive gel of undisclosed composition. The vaccine is pre-
sented as a liquid solution at room temperature, which enables sub-
lingual delivery with an oral dropper, and transforms into a gel upon
contact with the oral mucosa. Typical thermo-responsive gel formula-
tions that gelate at a temperature above 30 °C are based on polymers,
such as poloxamer and mucoadhesive polysaccharides. The gel matrix
enables adherence (retention N20 min.) to the sublingual mucosa
thereby preventing rapid clearance caused by salivation or swallowing
and protecting the vaccine antigen from degradation caused by salivary
enzymes. Vaccinating mice with a gel formulation containing tetanus
toxoid elicits high levels of IgG and IgA in serum as well as in secretions
of themouth, gastrointestinal and reproductive tract. Currently, PATH is
evaluating (pre-clinically) whether the addition of a mucosal adjuvant,
dmLT, can contribute to the efficacy of sublingual vaccination using
thermo-responsive gel formulations [69].
4.1. Sprays
Sublingual sprays have been used for years for the sublingual admin-
istration of nitroglycerine to patients in order to counter an acute angina
pectoris. The most used nitroglycerine sprays are based on a formula-
tion containing the drug substance, ethanol, a small amount of mint
oil and a propellant, like tetrafluoroethane, to aerosolize the formula-
tion. We are not aware of any investigations into direct spraying of the
vaccine onto the sublingual or buccal mucosa.
A few studies, however, have applied vaccine sprays into the whole
mouth. Immunization of humanswith influenzawhole inactivated virus
(H1N1) without additives, such as an oral spray using a simple nasal
spraying device (no use of propellant), did not result in IgA antibody re-
sponses in nasal secretions and only resulted in marginally increased
IgA antibodies in saliva. Although no stimulation of cytotoxic T cells
was shown, an increase in systemic influenza-specific antibodies was
found [70].
Towhat extent the immune response elicited by sublingual vaccina-
tion is the result of direct immune activation of the tonsils remains a
matter of debate. For example, it has been shown that direct immuniza-
tion via the tonsils can give rise to adequate immune responses. Oral
spray immunization with replication-deficient viral vector vaccines
encoding simian immunodeficiency virus (SIV) sprayed directly on the
tonsils of rhesus macaques induced cellular and humoral immune re-
sponses. Additionally, after SIV challenge viral RNA levels were equally
reduced after systemic vaccination and vaccination through the use of
the oral mucosal spray [139].Fig. 3.Multi-layered films or tablets. The layers ofmulti-layered dosage forms have differ-
ent functions.4.2. Controlled release formulations
Several oral formulations are already licensed or are in development
for drug delivery in the mouth. Based on their drug release kinetics and
manufacturing method they can be categorized as: I) orally disinte-
grating preparations (tablets and fast-dissolving films) and II) extended
(slow) release tablets and films. Although their value for sublingual and
buccal delivery of antigens has not yet been extensively evaluated, they
will be described briefly in the next section since they may play an im-
portant role in the development of potent and thermo-stable sublingual
vaccines.
4.2.1. Orally disintegrating preparations
Orally disintegrating tablets for sublingual or buccal delivery are in
general relatively small and porous. Tablets for buccal delivery facilitate
fast disintegration and drug or vaccine release without inclusion of a
disintegrant. In general, these tablets dissolve within a few seconds
after being placed in the mouth without water, making them dried
(stable) alternatives for droplets.
Recently, several excipients were studied for their wafer formation
abilities (highly porous tablets made by direct compression) with the
intention to formulate wafers containing HPV vaccine for sublingual
vaccination [71]. A typical fast-disintegrating formulation for the gener-
ation of wafers with a diameter of 4 mm that showed a dissolution
time of less than 25 s (in 3 ml at 37 °C) consisted of approximately
65% (w/w)myo-inositol (the placebo HPV powder) and 35%microcrys-
talline cellulose (MCC) [71].
4.2.2. Extended release films and tablets
To effectively vaccinate via the sublingual and buccal mucosae, the
contact time of the antigen with the mucosa is expected to be critical,
although this remains to be demonstrated. Sustained release dosage
forms adhere to the mucosa and direct transport of the antigen to the
mucosa may improve the efficacy of sublingual and buccal vaccination.
In this regard, extended release films or tablets that consist of multi-
ple layers with different functions (Fig. 3) may be applied. The sub-
lingual mucosa is exposed to a high saliva flow, which might be
advantageous for a better swelling and dissolution of oral tablets. On
the other hand, it might also cause loss of the antigen and adjuvant
due to salivarywashout. Therefore, themuch lower saliva flowof buccal
mucosamakes this route probably a better target for a sustained release
system.
Extended release tablets are typically based on gelling hydrophilic
polymers, so-called hydrophilic matrix tablets. The polymers form a
gel layer around the tablet when they make contact with water. The re-
lease profile is controlled by the overall swelling and erosion [72]. Most
polymers that are used asmucoadhesives are hydrophilic polymers that
gelate upon contactwith saliva, allowing adherence to the buccalmuco-
sa by interfacial forces, such as hydrogen bonding, electrostatic interac-
tion as well as van der Waal's bonds.
Borde et al. [73] prepared extended release tablets for the model
antigen ovalbumin, based on two-layer tablets consisting of a muco-
adhesive layer, which is composed of carbopol, and a controlled release
layer. Since the tablets were not able to adhere to the floor of themouth
in mice, the tablets were applied upside down to the ventral side of
the tongue, resulting in the release of the antigen toward the sublingual
region. Immunization studies were performed with tablets contain-
ing 250 μg ovalbumin directly followed by sublingual administration
of a 1 μg/ml CT solution (7.5 μl) as adjuvant. Immunization with a fast-
releasing tablet was favorable over extended release formulations and
comparable to the liquid reference (ovalbuminwith CT) for the immune
response. However, the production of salivawas induced by administer-
ing pilocarpine subcutaneously before administering the tablet to pro-
vide better swelling and adhesion of the tablets [73]. The authors
concluded that extended release formulations for sublingual vaccination
have to be investigatedmore in detail. Extended release formulations for
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lingual mucosa. This will improve the antigen diffusion and prevent the
salivary washout and the impact of enzymes by shielding.
Extended release films based on multiple layers are generally made
by the solvent casting method [74] for which the antigen is added to a
coating mass (e.g., cellulose, polysaccharides) and subsequently cast
onto a film application apparatus. After drying and solvent evaporation,
the films can be cut into single doses.
The viscosity and density of the coatingmass are critical for success-
ful film casting (layer-by-layer coating). Moreover, the vaccine antigen
needs to be formulated in the coating mass with proper excipients to
guarantee resistance to the applied drying stresses [75]. Formulations
that have been proven to protect vaccines during the fabrication of
coated solid dosage forms have been described in literature but are
not yet used to produce vaccine-containing films. For example, the
group of Prausnitz applied formulations based on trehalose, surfactant
(poloxamer) and a polymer (PVP) to coat microneedles with vaccines
such as the whole inactivated influenza virus [76] and measles [77] for
dermal vaccination. An additional advantage of dried formulations is
the improved thermal stability during storage.5. Perspectives
The oralmucosae, in particular the sublingual and buccal regions are
attractive sites for the delivery of antigens, since their accessibility, non-
invasive and (immunological) advantages over other (mucosal) routes
(Section 2.1). Therefore, sublingual vaccine delivery has gained signifi-
cant attention during the past few years, as shown by the numerous
pre-clinical studies published in the last decade (Table 2).
The preclinical proof of concept of the sublingual route for vaccine
delivery has been proven for several antigens. In general, high doses of
antigen (10–500 μg) are administered in mice using a multiple dosing
regimen (Table 2). However, well-designed studies including proper
dose response and tracking (PK/PD) studies are still lacking. Never-
theless, the use of strong mucosal adjuvants seems to be necessary to
induce protective immune responses upon sublingual vaccination
using inactivated vaccines. Reported studies on screening and compar-
ison of adjuvants for sublingual vaccination, unfortunately, are still lim-
ited. Of the adjuvants investigated thus far (CT, CTB, LT, LTB, mLT, dmLT,
CpG, c-di-GMP, L18-MDP, FSL-1, Poly(I:C), MPLA, Pam3CSK4, R848,
murabutide, peptidoglycans, vitamin D3, chitosan and poly-gamma-
glutamic acid), enterotoxins (and their mutants) and TLR-9 agonists re-
sulted in the highest antibody responses whereas the other adjuvants
did not improve immune responses upon sublingual delivery. The
most used adjuvants for sublingual vaccine delivery are the enterotoxins
CT and LT, which are considered too toxic for human use. However, ge-
netically definedmutants of these toxins,which have reduced orminimal
toxicity, seemed to be promising adjuvants to augment both systemic
and mucosal immunity in response to sublingual administration.
Recombinant live carriers expressing the vaccine antigen seemed to
elicit protective immunity by inducing both antigen-specific systemic as
well as mucosal antibodies at distinct mucosal sites [28,32]. The exact
advantage of such live vaccines over inactivated vaccines is still not
clear, but it could be related to factors such as receptor-mediated up-
take, intracellular replication of antigens and co-delivery of immune po-
tentiators and antigens to APCs.
An approach that resembles the characteristics of the live pathogens,
e.g., by co-delivery of immune potentiator and antigen, is needed to de-
velop an effective inactivated (subunit) vaccine for the sublingual route.
Unfortunately, to date, limited studies have focused on such approaches
that use tailored formulations, such as nanoparticles or conjugated anti-
gen–adjuvant formulations. In the design of these formulations,
mucoadhesive or receptor-binding properties may be built in to in-
crease interaction with the oral mucosa and thereby facilitate antigen
uptake.In addition to delivery systems, dosage forms may improve the effi-
cacy of sublingual and buccal vaccines. Today, research on dosage form
optimization for sublingual or buccal vaccination appears marginal. The
few reported studies use mouse models to evaluate sublingual vaccina-
tion in vivo. Nevertheless, the small space under the tongue of animals
used for preclinical studies makes testing of sublingual solid dosage
forms challenging. For example, Muragappan et al. faced the problem
that sublingual tablets were not able to dissolve under the tongue of
mice [40]. Moreover, two-layered extended release tablets failed to ad-
here to the floor of the mouth in mice, resulting in a suboptimal admin-
istration that applied the tablet upside down on the ventral side of the
tongue [73]. Potential problems related to the sublingual application
of slow release formulations are due to the lack of an expanse of smooth
or (relatively) immobile mucosa, which make it difficult to keep the
dosage form in contact with the sublingual mucosa. Other dosage
forms, such as wafers, films and thermo-responsive gels, should be ex-
plored as these may likely increase the potential of sublingual vaccine
delivery. Sustained dosage forms (e.g., multi-layered oral films or tab-
lets) are probably better suited for application on the buccal mucosa,
which is considerably less permeable than the sublingual mucosa. The
few current studies on buccal vaccine delivery use buccal injections in-
stead of a topical application. However, the development of the extend-
ed release formulations would make topical buccal cheek vaccination
easier. Compared to the sublingual route, buccal administration in
small animals, such as mice, is more complicated since the buccal com-
partment has a minimal anatomical barrier with the sublingual com-
partment. Besides the animal size, the anatomical features of the oral
cavity should be taken into account, because of the specialized histolog-
ical characteristics and immunological competences of the oralmucosae
in humans. However, most rodents, such as mice, rats and hamsters,
have buccal mucosa that contains keratinized epithelium, in contrast
to non-keratinized epithelium of sublingual and cheek mucosae in
human. For buccal cheek administration, other animal models such as
rabbits, dogs and pigs are more appropriate since they contain non-
keratinized buccal mucosae. Moreover, the thickness of the buccal mu-
cosa in these animal models (rabbit, 600 μm; dog and pig, 770 μm) is
comparable to that of humans (500–800 μm) [78]. Current literature
does not address to which extent mucoadhesive formulations increase
the delivery of the antigen to oral mucosal APCs after sublingual or buc-
cal administration, requiring proper tracking (pharmacokinetics, PK)
studies in relation with immunological outcome (pharmacodynamics,
PD) in adequate animal models (Table 3).
To select suitable formulations and dosage forms, an in vitromodel
for the mucosa that can predict the transport of an antigen might
be useful. Porcine buccal mucosa is often chosen for in vitro studies on
buccal delivery of medicines because of its close resemblance to
human buccal mucosa with respect to structure, enzyme activity as
well as permeability characteristics [79]. However, mechanistic studies
evaluating the conditions for sublingual or buccal antigen delivery,
such as optimal contact time of the dosage form and the differences be-
tween the oral mucosal routes, are lacking in literature. Moreover, the
importance of specific molecular features of the antigen and/or antigen
formulation, such as size (e.g., 1–10 nm proteins versus 10–250 nm vi-
ruses versus 250 nm–2 μm bacteria), surface charge or specific receptor
ligands, is still not investigated systematically.
Most pre-clinical studies (in vivo animal models) are used to evalu-
ate the vaccine candidate's efficiency to induce protective mucosal
(and systemic) immunity. Secretory IgA (sIgA) provides antigen-
specific immune protection in mucosal tissues. As a result, most pre-
clinical studies on sublingual vaccination include the detection of sIgA
in mucosal secretions. Unfortunately, most studies are designed for an
optimal readout of systemic immune responses, making assumptions
on mucosal immunity not fully conclusive. Moreover, in general, the
presence of sIgA is determined in saliva, which is not the best readout
for mucosal immunity, especially for rodents [80]. A more predictive
method to measure mucosal immunity in mucosal tissues of rodents is
Table 3
Current challenges in the development of sublingual and buccal vaccines.
Challenges Research should focus on:
Get more insight into pharmacokinetics
and pharmacodynamics (PK/PD)
- Dose response studies
Dose-sparing possibilities
Multiple dose regime needed?
Potent and safe adjuvants
- In vivo imaging (tracking) studies
Get more insight into immunological
mechanisms
- Role of oral DCs upon buccal/sublingual
immunization
- Antigen uptake and transport
- Interactions of antigen and immune cells
- Use of proper animal models
- Readouts for mucosal immunity
Development optimized vaccine
formulations and proper dosage
forms
- Tailored vaccine delivery Oral DCs as
vaccine target
- Stable vaccine formulations
- Optimal contact time (mucoadhesive)
- Optimal antigen release time
- Use of proper animal models
Development of predictive assays
for mucosal immunity
- Optimal sampling for mucosal readout
- Validated assays for (pre-)clinical studies
591H. Kraan et al. / Journal of Controlled Release 190 (2014) 580–592the ‘Perfext method’, which is a direct method for quantitative assess-
ment of in vivo antibody or cytokine production at the local level [81].
Themethod uses the collection of heparinized mucosal tissue of the an-
imal followed by detergent treatment and the detection of antigen-
specific antibodies by ELISA [53,55].
Based on several pre-clinical studies, it would be highly interesting
to follow the expected upcoming clinical studies on sublingual vaccine
delivery (using live attenuated vaccines). These studies should build
on the experience of previous preclinical studies that were designed
to evaluate mucosal immunity as a correlate of protection, which
would require standardized and validated assays predictive of mucosal
immune protection [82]. For example, a method described by Saletti
et al. allows measurements of both systemic and mucosal antibody
responses to vaccines by detecting antigen-specific plasmablasts with
a specific mucosal pedigree (e.g., α4β7, CCR10) on small amounts of
whole blood [83]. Although it was developed for clinical samples, a
certain type of mucosal readout would also be useful for pre-clinical
studies, amid limited blood volumes that can be sequentially with-
drawn from small animals. The full benefits of sublingual vaccination
can only be revealed by the determination of both local and systemic
responses.
Current literature on sublingual and buccal vaccination with a broad
range of antigens provides a strong base for further testing of these non-
invasive vaccine delivery routes. This testing should includemechanistic
studies on the superiority of live vaccines over inactivated antigens, in-
cluding dose–response studies (Table 3). Based on the findings, tailored
vaccine formulations for inactivated antigens may be designed in the
near future. Development of these sophisticated formulations and opti-
mized dosage forms that facilitate antigen uptake by the oral mucosa
will be an important step forward toward successful sublingual and/or
buccal vaccination. Finally, upcoming clinical studies that confirm the
suggested safety and efficiency (by proper readout of both mucosal
and systemic immunity)may result in thefirst approved sublingual vac-
cination strategy.References
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